search
Back to results

Observational Study of Prosthetic Tissue Aortic and Mitral Heart Valve (EPIC)

Primary Purpose

Valvular Heart Disease

Status
Completed
Phase
Not Applicable
Locations
Study Type
Interventional
Intervention
EPIC
Sponsored by
Abbott Medical Devices
About
Eligibility
Locations
Outcomes
Full info

About this trial

This is an interventional treatment trial for Valvular Heart Disease focused on measuring heart valve, mitral, aortic, valvular disease

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria: The patient requires replacement of the aortic and/or mitral valve (Note: Patients undergoing concomitant procedures, e.g. coronary artery bypass grafting, valve repair, are eligible for this study). The patient (or legal guardian) has signed a study-specific informed consent, agreeing to the data collection and follow-up requirements. The patient is of legal age in host country. Exclusion Criteria: Patient already has a prosthetic valve, other than the aortic and/or mitral valve being replaced at this time. The patient requires replacement of the tricuspid or pulmonary valve. The patient is pregnant or nursing. Patient has active endocarditis. Patient is actively participating in the study of an investigational drug or device. Patient has had an acute preoperative neurological event. The patient is undergoing renal dialysis. Patient is an intravenous drug abuser, alcohol abuser or prison inmate. Patient has an inability or unwillingness to return for the required follow-up intervals. The patient had the SJM Epic Valve implanted during the clinical study but then had the bioprosthesis explanted.

Sites / Locations

    Outcomes

    Primary Outcome Measures

    Adverse effect rates
    Clinical status as indicated by NYHA functional classification
    Hemodynamic performance

    Secondary Outcome Measures

    Full Information

    First Posted
    May 23, 2006
    Last Updated
    February 1, 2019
    Sponsor
    Abbott Medical Devices
    search

    1. Study Identification

    Unique Protocol Identification Number
    NCT00329667
    Brief Title
    Observational Study of Prosthetic Tissue Aortic and Mitral Heart Valve
    Acronym
    EPIC
    Official Title
    An Observational, Prospective Evaluation of the SJM Epic Valve
    Study Type
    Interventional

    2. Study Status

    Record Verification Date
    February 2019
    Overall Recruitment Status
    Completed
    Study Start Date
    January 2003 (undefined)
    Primary Completion Date
    March 2006 (Actual)
    Study Completion Date
    September 2008 (Actual)

    3. Sponsor/Collaborators

    Name of the Sponsor
    Abbott Medical Devices

    4. Oversight

    5. Study Description

    Brief Summary
    This study is a multi-center, prospective, non-randomized, observational study. The objectives of this study are to confirm the clinical safety and efficacy of the SJM Epic valve.
    Detailed Description
    This study is a multi-centered, multi-country, prospective, non-randomized, observational study, without concurrent or matched controls, conducted under a common protocol. Bayesian methods will be used for the design and analysis of this study. The Bayesian model will determine if the data for the valve configurations are poolable. Bayesian methods also provide a means of determining the appropriate stopping time for the study based on the amount of information generated. The objectives of this study are to confirm the clinical safety and efficacy of the SJM Epic Valve by establishing the following: adverse effect rates clinical status as indicated by NYHA functional classification hemodynamic performance

    6. Conditions and Keywords

    Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
    Valvular Heart Disease
    Keywords
    heart valve, mitral, aortic, valvular disease

    7. Study Design

    Primary Purpose
    Treatment
    Study Phase
    Not Applicable
    Interventional Study Model
    Single Group Assignment
    Masking
    None (Open Label)
    Allocation
    Non-Randomized
    Enrollment
    761 (Actual)

    8. Arms, Groups, and Interventions

    Intervention Type
    Device
    Intervention Name(s)
    EPIC
    Intervention Description
    Surgical replacement of a diseased, damaged, or malfunctioning native or prosthetic aortic and/or mitral heart valves
    Primary Outcome Measure Information:
    Title
    Adverse effect rates
    Time Frame
    Ongoing
    Title
    Clinical status as indicated by NYHA functional classification
    Time Frame
    At required follow-up visits
    Title
    Hemodynamic performance
    Time Frame
    At required follow-up visits

    10. Eligibility

    Sex
    All
    Minimum Age & Unit of Time
    18 Years
    Accepts Healthy Volunteers
    No
    Eligibility Criteria
    Inclusion Criteria: The patient requires replacement of the aortic and/or mitral valve (Note: Patients undergoing concomitant procedures, e.g. coronary artery bypass grafting, valve repair, are eligible for this study). The patient (or legal guardian) has signed a study-specific informed consent, agreeing to the data collection and follow-up requirements. The patient is of legal age in host country. Exclusion Criteria: Patient already has a prosthetic valve, other than the aortic and/or mitral valve being replaced at this time. The patient requires replacement of the tricuspid or pulmonary valve. The patient is pregnant or nursing. Patient has active endocarditis. Patient is actively participating in the study of an investigational drug or device. Patient has had an acute preoperative neurological event. The patient is undergoing renal dialysis. Patient is an intravenous drug abuser, alcohol abuser or prison inmate. Patient has an inability or unwillingness to return for the required follow-up intervals. The patient had the SJM Epic Valve implanted during the clinical study but then had the bioprosthesis explanted.

    12. IPD Sharing Statement

    Learn more about this trial

    Observational Study of Prosthetic Tissue Aortic and Mitral Heart Valve

    We'll reach out to this number within 24 hrs